Navigation Links
New cell transplantation technique restores insulin production in diabetics

Researchers are using a new cell transplantation technique to restore the cells that produce insulin in patients with type 1 diabetes. The method is minimally invasive, with few complications. The study was presented today at the annual meeting of the Radiological Society of North America (RSNA).

"We used ultrasound guidance to inject donor cells into the portal vein of diabetic patients, which is accessed through the skin," said co-author Saravanan Krishnamoorthy, M.D., radiology resident at the University of Minnesota in Minneapolis. "This is a safe method of cell transplantation that could potentially become a same-day procedure."

In type 1 diabetes, the body does not produce insulin. This typically results from the destruction of insulin-producing islet beta cells in the pancreas. Insulin is necessary to metabolize sugar, which is the basic fuel that all cells need.

With this minimally invasive technique, donor islet cells are injected into diabetic patients so that the new, healthy islet cells can restore insulin production, essentially stopping the progression of the disease. The study included 13 patients with poorly controlled type 1 diabetes. Fifteen islet cell transplants were completed-two patients underwent two procedures to achieve correct needle placement.

"We used a steroid-free protocol to suppress the immune system, so that the body accepted the transplanted cells," Dr. Krishnamoorthy said. "We also developed a 'sandwich technique' to close the access site through the skin, where the islet cells are injected. The sandwich technique is so-called because of the layered applications of gelfoam and coil used to close the access site."

Dr. Krishnamoorthy said that even though percutaneous islet cell transplantation is currently an experimental procedure, the sandwich closure is a safe method that prevents many of the complications common to previous techniques used to transplant islet cells. Thirty days after the pr
'"/>

Source:Radiological Society of North America


Page: 1 2

Related biology news :

1. Monkeying around to improve organ transplantation
2. Diabetes researchers pioneer islet cell xenotransplantation in primate studies
3. Guiding principles for facial transplantation unveiled
4. Plastic surgeons countdown first full facial transplantation
5. Successful transplantation from pig embryos to mice
6. Researchers create genetically matched embryonic stem cells for transplantation
7. New lab technique identifies high levels of pathogens in therapy pool
8. Brain-mapping technique aids understanding of sleep, wakefulness
9. Study reveals new technique for fingerprinting environmental samples
10. Researchers pioneer new gene therapy technique using natural repair process
11. Newer imaging techniques may lead to over-treatment
Post Your Comments:
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... two Texas AgriLife Research scientists later turned into a ... female sheep. Female sheep (ewes) are an agriculturally important ... for studying the physiology of human pregnancy, the researchers ... treat male erectile dysfunction, enhanced blood flow in pregnant ...
... scientists have warned of the possible negative health effects ... from plastic water bottles and food packaging to sunglasses ... disorders, obesity, abnormal brain development as well as breast ... Drug Administration announced that it was concerned about "the ...
... new way of preventing potentially harmful plasticizers the source ... of the most widely used groups of plastics. The advance ... plastics that are safer than those now used in packaging, ... is in ACS, Macromolecules , a bi-weekly journal. ...
Cached Biology News:Study shows male erectile dysfunction drug enhances fetal growth in female sheep 2Mother's exposure to bisphenol A may increase children's chances of asthma 2
(Date:12/15/2014)... Dec. 15, 2014  Ascendis Pharma A/S, a ... to address significant unmet medical needs, today announced ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  This interim analysis consists of 25 patients, ... in the study, completing all six months of ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 The ... million in 2013, and is expected to grow ... 2019. , Browse through the TOC of the ... industry trends and segments, with help of various ... The global DNA Microarray market consists of instrument, ...
(Date:12/13/2014)... 2014 QuickSTAT is making significant investments ... Chain capabilities, and is delighted to announce the opening ... serve Life Science clients in the region. , QuickSTAT ... warehouse, will provide 24/7 transportation and logistics services, as ... patient-clinical specimens, API, following IATA rules and EU GDP ...
(Date:12/13/2014)... ANTONIO , Dec. 12, 2014  Janssen Research ... data at the San Antonio Breast Cancer Symposium (SABCS) ... plus best supportive care (BSC) versus BSC when used ... receiving standard chemotherapy. This non-inferiority trial did not meet ... 15 percent or greater increase in the risk of ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12
... to Launch into High Growth Brazilian Market for ... Aesthera announced today the receipt of ANVISA clearance ... platforms in Brazil. ANVISA (Agencia Nacional de ... and regulatory agency charged with clearing all applications ...
... Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") ... to date this year and guidance on its projected financial ... , ... 4.60 million (US $0.68 million), representing a 127 percent increase ...
... , Connecticut MORRISVILLE, N.C., May 20 Asymchem ... and Drug Products to the pharmaceutical industry, with sites in ... award by Pfizer Inc. as the 2008 Top Intermediates CMO ... center on May 1, 2009. The award was the first ...
Cached Biology Technology:Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 2Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil 3Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 2Sinobiopharma Updates on Progress; Projects Increases in Sales and Revenues In 2009 3Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem 2